Physician profile
Kimberly J Butterwick
NPI 1760522080
$94,196.50
in general payments reported to CMS, 2019-2025
10 companies · $4,192 in 2025
The $4,192 reported for 2025 was more than what 87% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $26K · 2021: $474 · 2022: $12K · 2023: $4,048 · 2024: $23K · 2025: $4,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $2,473 · Travel and Lodging: $901 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $780 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,200.00 |
| Food and Beverage | $2,473.01 |
| Travel and Lodging | $900.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $780.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54,789.17 | 2019-2022 | |
| Abbvie INC. | $25,798.22 | 2023-2025 | Botox |
| Merz North America, INC. | $8,225.00 | 2019-2025 | Xeomin |
| Revance Therapeutics, INC. | $3,370.40 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $1,603.33 | 2019-2025 | Dysport |
| Solta Medical, A Division of Bausch Health US, LLC | $155.41 | 2019-2023 | |
| Almirall LLC | $150.00 | 2019 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.43 | 2019 | |
| Biofrontera INC. | $16.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Butterwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.